Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

Horsley, Alex; Davies, Jane C.; Gray, Robert D.; Macleod, Kenneth; Donovan, Jackie; Aziz, Zelena A.; Bell, Nicholas; Rainer, Margaret; Mt‐Isa, Shahrul; Voase, N.; Dewar, Maria H; Saunders, Clare; Gibson, James Sr; Parra-Leiton, Javier; Larsen, Mia; Jeswiet, Sarah; Soussi, Samia; Bakar, Yusura; Meister, Mark G.; Tyler, Philippa; Doherty, Ann; Hansell, David M.; Ashby, Deborah; Hyde, Stephen C.; Gill, Deborah R.; Greening, A P; Porteous, David J.; Innes, J A; Boyd, Alan; Griesenbach, Uta; Cunningham, Steve; Alton, Eric W.F.W.

doi:10.1136/thoraxjnl-2012-202538

Cited by 127 publications

(166 citation statements)

References 32 publications

(26 reference statements)

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Although CRP and SAA are nonspecific acute-phase reactants, calprotectin and G-CSF are markers of neutrophilic inflammation that might be more informative in tracking disease activity and response to therapy in CF. Circulating calprotectin has shown greater change than other systemic or sputum markers of inflammation with exacerbation treatment (19,20). Interestingly, G-CSF was the only protein that was higher at the clinically stable follow-up visit than at exacerbation onset.…”

Section: O2 Saturationmentioning

confidence: 93%

Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation

et al. 2015

View full text Add to dashboard Cite

Rationale: In cystic fibrosis (CF), pulmonary exacerbations present an opportunity to define the effect of antibiotic therapy on systemic measures of inflammation.Objectives: Investigate whether plasma inflammatory proteins demonstrate and predict a clinical response to antibiotic therapy and determine which proteins are associated with measures of clinical improvement.Methods: In this multicenter study, a panel of 15 plasma proteins was measured at the onset and end of treatment for pulmonary exacerbation and at a clinically stable visit in patients with CF who were 10 years of age or older.Measurements and Main Results: Significant reductions in 10 plasma proteins were observed in 103 patients who had paired blood collections during antibiotic treatment for pulmonary exacerbations. Plasma C-reactive protein, serum amyloid A, calprotectin, and neutrophil elastase antiprotease complexes correlated most strongly with clinical measures at exacerbation onset. Reductions in C-reactive protein, serum amyloid A, IL-1ra, and haptoglobin were most associated with improvements in lung function with antibiotic therapy. Having higher IL-6, IL-8, and a 1 -antitrypsin (a1AT) levels at exacerbation onset were associated with an increased risk of being a nonresponder (i.e., failing to recover to baseline FEV 1 ). Baseline IL-8, neutrophil elastase antiprotease complexes, and a1AT along with changes in several plasma proteins with antibiotic treatment, in combination with FEV 1 at exacerbation onset, were predictive of being a treatment responder. Conclusions:Circulating inflammatory proteins demonstrate and predict a response to treatment of CF pulmonary exacerbations. A systemic biomarker panel could speed up drug discovery, leading to a quicker, more efficient drug development process for the CF community.

show abstract

Section: O2 Saturationmentioning

confidence: 93%

Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…During last decades, an increased interest for MBW method among patients suffering from CF has been noted [3,4,[33][34][58][59][60][61][62][63] MBW is a non-invasive method, feasible to be performed and without the risk of radiation exposure [64]. A lot of studies have suggested that LCI has the advantage over FEV 1 to detect CF lung disease in earlier stages [21,36,38,[64][65][66][67][68].…”

Section: Discussionmentioning

confidence: 99%

Is Lung Clearance Index (LCI) Affected by the Severity of Lung Disease in CF?

Avramidou¹,

Hatziagorou²,

Kampouras³

et al. 2017

J Pulm Respir Med

View full text Add to dashboard Cite

“…77 More recently, calprotectin has been analyzed to monitor decreasing inflammation resulting from therapy after an acute exacerbation. 78 In preeclampsia, Braekke et al 79 examined 62 pregnant women reporting median maternal plasma concentrations were higher in the preeclampsia group compared with the control group (1.08 mg/L versus 0.55 mg/L, p < 0.001); others reported similar trends. 80 Fortyone children with different types of juvenile idiopathic arthritis (JIA), unrelated connective tissue disorders (CTDs), or otherwise healthy were evaluated to see if FC could be used to assess subclinical gut inflammation.…”

Section: Applications In Other Diseasesmentioning

confidence: 67%

Calprotectin: Clinical Applications in Pediatrics

Herrera

Christensen

Helms

2016

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding. We surveyed all published studies in English of calprotectin in neonates, infants, children, and adolescents through February 2014. We will discuss calprotectin's basic properties and analysis such as characteristics, identification, presence in body fluids, and maturational development. In addition, calprotectin's use in inflammatory diseases exploring both GI and non-GI conditions will be evaluated and compared with other serum markers presently available. Finally, a summary of our findings and discussion of future work that could be undertaken in order to render calprotectin as a more useful monitoring tool to the medical research community will complete the review.

show abstract

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation

Cited by 127 publications

References 32 publications

Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation

Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation

Is Lung Clearance Index (LCI) Affected by the Severity of Lung Disease in CF?

Calprotectin: Clinical Applications in Pediatrics

Contact Info

Product

Resources

About